Gliatech (GLIA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (689)	3/24/1999 3:36:00 PM
From: scaram(o)uche	of 2001

We shareholders need to know that various innovative alternatives are being considered, going forward. Oesterling et al. have done a sensational job of negotiating the company to a position of marked flexibility and leverage. However, we investors are greedy and impatient bastards, and we need to know that GLIA is continuing to innovate and considering stuff like "Chiron-like, 49% deals" with potential suitors. Option three..... it seems, to me, that GLIA could negotiate a deal (Adcon royalties, no milestones) that includes marketing rights to the Adcon products and 49% of the company......... about $300 million, if they (we!) make it through multiple dose phase I for 2331. This would allow GLIA to move forward as an independent entity, while garnering the resources to (1) independently develop the H3 receptor antagonist and agonist programs, and (2) play an important role in sector consolidation through acquisitions.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next